Bimekizumab Long-term Efficacy in Patients with Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s433. https://doi.org/10.25251/skin.8.supp.433